Medical devices, healthcare technology and the business of care
510(k) clearance · K261336

Xpert Respiratory Panel

Cepheid · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONK261336

What did the FDA decide?

Cepheid received a substantially equivalent (SESE) determination for the Xpert Respiratory Panel under 510(k) K261336, with a decision date of September 25, 2026, in the microbiology specialty under product code QOF. The submission sought clearance by demonstrating substantial equivalence to the QIAstat-Dx Respiratory Panel Plus (K233100) for use on GeneXpert Instrument Systems. SESE denotes 510(k) clearance, not premarket approval.

The panel is a qualitative multiplexed in vitro diagnostic that detects and identifies DNA and RNA from listed respiratory bacteria and viruses, including SARS-CoV-2, in nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory tract infection. It runs on GeneXpert Dx, Infinity and Touchscreen systems with specified software versions, and is labeled for prescription use only. The source does not record performance data, so comparative analytical results remain unknown.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Sep 25, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261336
Regulatory pathway
510(k) premarket notification
Applicant
Cepheid
Product code
QOF
Decision code
SESE
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.

Applicant
Cepheid
Product code
QOF
FDA device class
2

FDA decision timeline

  1. K261336 received

    Application receipt date recorded by FDA.

  2. K261336 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QOF

Product / regulatory recordCompanyPathwayDecision dateSource
GenMark Diagnostics, Inc.510(k) clearanceOct 30, 2026FDA
Cepheid510(k) clearanceOct 22, 2026FDA
Cepheid510(k) clearanceOct 2, 2026FDA
Biofire Diagnostics510(k) clearanceSep 22, 2026FDA
Baebies, Inc.510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cepheid

Headquarters
Not reported
Brand website
cepheid.com
FDA applicant address
Sunnyvale, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records